Huang, J.; Li, L.; Xu, L.; Feng, L.; Wang, Y.; SIK, A.G.; Jin, M.; Wang, R.; Liu, K.; Li, X.
Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways. Mar. Drugs 2025, 23, 47.
https://doi.org/10.3390/md23010047
AMA Style
Huang J, Li L, Xu L, Feng L, Wang Y, SIK AG, Jin M, Wang R, Liu K, Li X.
Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways. Marine Drugs. 2025; 23(1):47.
https://doi.org/10.3390/md23010047
Chicago/Turabian Style
Huang, Jing, Lei Li, Liyan Xu, Lixin Feng, Yuxin Wang, Attila Gabor SIK, Meng Jin, Rongchun Wang, Kechun Liu, and Xiaobin Li.
2025. "Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways" Marine Drugs 23, no. 1: 47.
https://doi.org/10.3390/md23010047
APA Style
Huang, J., Li, L., Xu, L., Feng, L., Wang, Y., SIK, A. G., Jin, M., Wang, R., Liu, K., & Li, X.
(2025). Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways. Marine Drugs, 23(1), 47.
https://doi.org/10.3390/md23010047
